Genfit (GNFT) Stock Price, News & Analysis

Company Overview

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Key Stats

• Today's Range: €5.14 to €5.42
• 50-Day Range: €3.66 to €5.70
• 52-Week Range: N/A
• Volume: 187,047 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNFT Stock Analysis - Frequently Asked Questions

How have GNFT shares performed this year?

Genfit's stock was trading at €3.54 on January 1st, 2024. Since then, GNFT shares have increased by 52.5% and is now trading at €5.40.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Advanced Micro Devices (AMD), Alibaba Group (BABA), FedEx (FDX), GameStop (GME), NightHawk Biosciences (NHWK), Nikola (NKLA) and United Parcel Service (UPS).

Industry, Sector and Symbol

• Stock Exchange: EPA
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: EPA:GNFT
• CUSIP: N/A
• CIK: N/A
• Web: www.genfit.com
• Phone: 33 3 20 16 40 00
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A